Cleveland Clinic Akron General, Akron, Ohio.
University of Illinois Medical Center, University of Illinois-Chicago College of Pharmacy, Chicago, Illinois.
J Clin Hypertens (Greenwich). 2019 Nov;21(11):1684-1692. doi: 10.1111/jch.13694. Epub 2019 Sep 25.
Hypertensive emergencies (HTNe) primarily focus on decreasing the blood pressure to specific targets. However, there are emerging data surrounding the potential clinical effects of blood pressure variability (BPV) in patients with HTNe. This narrative review highlights the various definitions of BPV, the emerging role of BPV, and the clinical data surrounding BPV in the HTNe setting. Clinical studies were obtained from a PubMed search through October 2018 utilizing PICO methodology. Original research articles, systematic reviews, and meta-analyses were considered for inclusion. Articles were selected for inclusion based on the relevancy of the article investigating BPV in the HTNe setting. There is currently no accepted standard to express BPV in the acute care setting of HTNe, and various parameters have been reported. There are very limited data regarding BPV outside of the neurologic HTNe setting. In the acute treatment phase of neurologic HTNe, BPV is consistently associated with increased risk of unfavorable outcomes. In the HTNe setting, continuous infusion of calcium channel blockers may optimize BPV compared to other agents. Based on current data, BPV should be investigated in a prospective systemic fashion. Efforts should be taken to ensure that BPV is minimized in the acute phase of HTNe, especially for those patients with intracranial hemorrhage. This reduced BPV is associated with improved favorable outcomes, but further study investigating specific pharmacologic agents is needed.
高血压急症(HTNe)主要侧重于将血压降低到特定目标。然而,目前有越来越多的数据围绕着 HTNe 患者血压变异性(BPV)的潜在临床影响。本综述强调了 BPV 的各种定义、BPV 的新兴作用以及 HTNe 环境中 BPV 的临床数据。临床研究通过 2018 年 10 月的 PubMed 搜索利用 PICO 方法获得。原始研究文章、系统评价和荟萃分析都被认为可以包含在内。基于文章调查 HTNe 环境中 BPV 的相关性,选择文章进行包含。目前,在 HTNe 的急性护理环境中没有表达 BPV 的公认标准,并且已经报道了各种参数。在 HTNe 以外的神经系统环境中,关于 BPV 的数据非常有限。在 HTNe 的急性治疗阶段,BPV 始终与不良结果的风险增加相关。在 HTNe 环境中,与其他药物相比,钙通道阻滞剂的连续输注可能会优化 BPV。基于当前数据,应系统地前瞻性地研究 BPV。应努力确保在 HTNe 的急性阶段将 BPV 降至最低,特别是对于那些患有颅内出血的患者。这种降低的 BPV 与改善的有利结果相关,但需要进一步研究调查特定的药物治疗。